Vyzulta®
Latanoprostene bunod is a nitric oxide-donating prostaglandin F2α analog that reduces IOP through dual mechanisms via both outflow pathways.
| Dosage Form | Ophthalmic Solution |
| Strength | 0.024% |
| Storage | Store at 2–8°C. |
| Category | Ophthalmics |
| Availability | Available for Transfer |
Open-angle glaucoma; ocular hypertension.
Metabolized to latanoprost acid (prostaglandin analog increasing uveoscleral outflow) and butanediol mononitrate (releasing nitric oxide, relaxing trabecular meshwork and increasing conventional outflow).
Each Burrard Pharmaceuticals technology transfer package for Latanoprostene Bunod includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.